Virax Biolabs Group (NASDAQ:VRAX) Receives “Buy” Rating from HC Wainwright

Virax Biolabs Group (NASDAQ:VRAX)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $1.00 price target on the stock, down from their previous price target of $3.00. HC Wainwright’s price objective would indicate a potential upside of 165.96% from the company’s current price.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Virax Biolabs Group in a research report on Tuesday, October 14th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $1.00.

Virax Biolabs Group Stock Performance

Shares of NASDAQ VRAX traded up $0.01 during mid-day trading on Friday, reaching $0.38. 38,985 shares of the company’s stock were exchanged, compared to its average volume of 426,657. Virax Biolabs Group has a 52-week low of $0.31 and a 52-week high of $2.61. The company’s 50-day moving average is $0.44 and its 200-day moving average is $0.63.

Virax Biolabs Group (NASDAQ:VRAX) last released its quarterly earnings results on Tuesday, December 2nd. The company reported ($0.27) EPS for the quarter. The firm had revenue of $0.00 million during the quarter.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.